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Abstract
Cystic fibrosis is mainly caused by mutations that interfere with the biosynthetic folding of the cystic fibrosis transmembrane conductance
regulator (CFTR) protein. The aim of this study was to find cellular proteins interacting with CFTR and regulating its processing. We have
used a genetic screen in yeast to identify such proteins and identified CSN5 that interacted with the third cytoplasmic loop of CFTR. CSN5
is the 5th component of the COP9 signalosome, a complex of eight subunits that shares significant homologies to the lid subcomplex of the
26S proteasome and controls the stability of many proteins. The present study shows that CSN5 associates with the core-glycosylated form
of CFTR and suggests that this association targets misfolded CFTR to the degradative pathway. Identifying CSN5 as a new component of
the degradative pathway is an important step towards the goal of unraveling the sorting between misfolded and correctly folded CFTR
proteins.
© 2008 Elsevier B.V. All rights reserved.Keywords: CFTR; CSN5; COP9 signalosome; Interaction and degradation1. Introduction
Cystic fibrosis (CF) is the most common severe autosomal
recessive genetic disorder in Caucasians. It is caused by muta-
tions in the cystic fibrosis transmembrane conductance regulator
(CFTR) gene which encodes a cAMP-regulated Cl− channel [1].
The most frequent mutation of CFTR, F508del (deletion of phe-
nylalanine at codon 508) induces a defective processing (class II)
where almost 100% of the newly synthesized F508del-CFTR
is degraded due to improper folding. The misfolded protein is
retained in the ER, retrotranslocated and then degraded by theAbbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane
conductance regulator; CSN, COP9 signalosome; ERAD, ER-associated
degradation; ERQC, ER-quality control
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doi:10.1016/j.bbamcr.2008.01.010ubiquitin proteasome pathway [2,3]. This process is called
endoplasmic reticulum (ER)-associated degradation (ERAD) (re-
viewed in Ref. [4–6]). Decrease of class II mutant protein
degradation by using proteasome inhibitors slow CFTR degra-
dation, but maturation does not increase concomitantly [2,7],
indicating that degradation and maturation are not in equilibrium
[8]. This implies therefore the possibility of additional mechan-
isms involved in the degradation of CFTR such as proteasome-
independent ERAD [9]. Hence, the strategies aiming to increasing
the maturation of these mutants will require a better understand-
ing of the underlying processes of their folding and intracellular
processing.
Initially, F508del-CFTR was not detected at the apical cell
membrane [10–12]; since then several studies have detected
either cAMP chloride conductance or apical localization of the
protein in CF patients [13–18]. More recent studies have shown
that cAMP-dependent Cl− secretion is absent from rectal tissues
freshly excised from F508del homozygous CF patients [19] or
from airway specimens freshly excised from F508del-CFTR
homozygous subjects [20]. These data raise the question of the
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that these mutants are associated with variable protein partners
that could modify the processing of CFTR during its course to
the cell surface.
CSN5 was originally identified as a co-activator of the c-Jun
transcription factor named Jun activation domain-binding pro-
tein 1 (Jab1) [21], and later as the fifth component of the COP9
signalosome (CSN), a complex of eight subunits that shares
significant homologies to the 26S proteasome lid subcomplex
[22]. This complex was first identified in Arabidopsis as a re-
pressor of photomorphogenesis [23], and is an evolutionarily
conserved protein complex that controls pleiotropic functions
in various eukaryotes ranging from cell cycle progression and
signal transduction to transcriptional regulation by regulating
specific protein degradation events. CSN regulates protein de-
gradation either through direct regulation of E3 ubiquitin ligases
[24–26] or through regulation of the phosphorylation of specific
substrates such as p53 and c-Jun [27,28].We have chosen to name
this protein CSN5 according to the nomenclature proposed by
Deng although the HUGO name is COPS5 [29].
Many mutations in cytoplasmic loops impair CFTR pro-
cessing, suggesting that the correct folding of these loops is
important for proper maturation of the whole protein. The
third cytoplasmic loop is highly conserved throughout CFTR
evolution and among ABC transporters [30], and contains
thoroughly investigated class II mutations [31,32]. The aim of
this study was to identify intracellular proteins capable of
interacting with CFTR and regulating its processing. For this
purpose, a yeast two-hybrid screening was performed using
the third cytoplasmic loop of CFTR as a bait. We have identi-
fied CSN5 as a binding partner and investigated the cellular
consequences of its expression on CFTR processing and
function. Here, we show that CFTR and CSN5 associate and
that this direct or indirect interaction targets misfolded core-
glycosylated CFTR to the ubiquitin proteasome system. There-
fore, this study emphasizes on the CSN5-CFTR interaction as
a novel step towards selection between misfolded and correctly
folded CFTR proteins during their processing.
2. Materials and methods
2.1. Antibodies and reagents
The following antibodies were used: MAB25031 (clone 24-1, R and D sys-
tems) and MM13-4 (Upstate) monoclonal antibodies (mAb) for CFTR detection,
mAb anti-V5 coupled with FITC for V5-tagged protein detection (Invitrogen),
a mouse mAb for CSN5 detection (Abcam) and α-Tubulin and Lamin B1
antibodies (Abcam). Fluorescence-labeled antibodies used: Alexa Fluor™ 488
and 568-coupled goat anti-mouse IgG2a or IgG2b isotypes respectively (Molecular
Probes). Horse radish peroxidase (HRP)-coupled secondary antibodies and pi-
ceatannol were purchased from Sigma-Aldrich.
2.2. Yeast two-hybrid screening
The sequence encoding the 52 amino acids corresponding to the 3rd
cytoplasmic loop (CL3) of CFTR was PCR-amplified using the following
oligonucleotide primers (5′-TGCATATGGCCATGGAGCTGGTGCATACTC-
TAATC-3′ and 5′-TGCGGCCGCTGCAGTAAGAGGCAGAAGGTCATC-3′)
and subcloned into NcoI-PstI sites of plasmid pGBKT7 (Clontech), generating
the bait plasmid: pGBKT7-CL3wt. This bait plasmid was transformed into yeaststrain AH109 Mat a. We used a pretransformed Human testis MATCHMAKER
cDNA library in yeast strain Y187 Mat α (Clontech), containing 3.5×106 inde-
pendent clones with an average length of 2 kb (0.4 to 4 kb). The library was
screened by mating before spreading on synthetic dropout (SD) medium, lacking
histidine, leucine, tryptophan and adenine, to select diploid clones. Positive
interactions were further confirmed by the LacZ+ phenotype. Absence of self-
activation was verified by mating the bait with a control prey and selection on SD
medium. To characterize the CL3-interacting proteins, plasmids were recovered
from yeast strains showing positive interactions, and their identity was determined
by DNA sequencing.
2.3. Plasmids constructs and site-directed mutagenesis
The entire coding sequences of the humanCSN5 cDNAwas PCR isolated from a
humanbrain cDNAlibrary and subcloned into the plasmid pcDNA3.1/V5-HisTopo®
(Invitrogen). CSN5 mutants (D151N and the four silent mutations: 5′-CAATCC-3′
(CSN5 nucleotide 398 to 403; Q23Q and S24S) were constructed using the Gene-
Editor kit (Promega) and the resulting mutants were fully sequenced. CFTR plasmids
were constructed in the expression vector pTracer-CMV (Invitrogen) as already
described [32–35].
2.4. Cell culture and transfection
HT-29 (ATCC, HTB-38), HEK (ATCC, CRL-1573), and stably transfected
HeLa cells expressing wild-type CFTR (spTCF-wt), F508del-CFTR (spTCF-
ΔF) or pTracer (spTracer) [36,37] were grown at 37 °C with 5% CO2 in DMEM
with Glutamax containing 10% fetal calf serum, 100 U/ml penicillin and 100 g/
ml streptomycin (all from Invitrogen).
All cells were grown on 60 or 100 mm diameter dishes. Subconfluent cells
were transfected by lipofection using Lipofectamine® and Plus reagent (Invi-
trogen) according to themanufacturer's instructions. Confluent monolayers were
harvested and used 24 or 48 h post-transfection for immunoprecipitation,
immunocytochemistry or functional assays.
2.5. Co-immunoprecipitation (Co-IP) and western blots
Cells grown on 100mmdiameter disheswere harvested 24 h after transfection
in PBS 1×, pelleted at 2000 g at 4 °C and resuspended in 600 μL Co-IP buffer
(50mMTris–HCl pH 7.4, 150mMNaCl, 5 mMKCl, 1 mMMgCl2, 1 mMCaCl2
5% glycerol and 1% NP-40) supplemented with complete protease inhibitors
(Roche Applied Sciences). After preclearing 1 to 5% of lysates were withdrawn
for input assays and the remainingmaterial was incubatedwith 0.8μgMAB25031
(R andD System) or 0.8 μg anti-CSN5 (Abcam) overnight at 4 °C. Pansorbin cells
were then added. The totality of the immunoprecipitated material was subjected
to SDS-PAGE and analyzed byWestern blotting. When endogenous Co-IPs were
performed two 100 mm dishes were pooled before loading.
Equal amounts of proteins, assayed by the Bradford technique (Pierce) were
loaded on 10% SDS-PAGE gels and then transferred to PVDF membrane (GE
Healthcare). Proteins were immunodetected by monoclonal or polyclonal anti-
bodies followed by HRP-conjugated anti-mouse or anti-rabbit IgGs, and vi-
sualized by chemiluminescence with the ECL+ kit (GE Healthcare), or West
Dura kit (Pierce). Antibodies were used at the following dilutions: MM13-4, 1/
2000; anti-CSN5, 1/5000; anti-Tubulin, 1/10000; V5-HRP, 1/5000; anti-mouse-
HRP, 1/50000. Direct recording of the chemiluminescence was performed using
the CCD camera of the GeneGnome analyzer and quantification using the
GeneTools software (Syngene BioImaging Systems, Synoptics Ltd).
2.6. Immunoprecipitation/PKA assay and pulse–chase experiments
Cells grown on 60mmdiameter dishes were harvested 48 h after transfection.
CFTR protein immunoprecipitation using MAB25031 (R and D System) was
performed as already described [32–35]. Briefly, cell lysates were mixed with
0.4 μg of MAB25031 and Pansorbin cells. The resulting proteins were phos-
phorylated in vitro with 5 units of the catalytic subunit of PKA (Promega)
and 10 μCi [γ-33P] ATP (GE Healthcare), separated by 5% SDS-PAGE, dried
and autoradiographed. Radioactivity was quantitated by radioanalytic scanning
(Molecular Dynamics PhosphoImager).
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lacking cysteine and methionine and then for 15 min in the same medium
containing 100 μCi/ml methionine and cysteine [35S]-labelled (Redivue Pro-
mix™ [35S] GE Healthcare). CFTR was then immunoprecipitated with
MAB25031.
2.7. Immunofluorescent staining
Immunofluorescent staining was performed as previously described [34]
except cells were fixed in cold acetone and incubated overnight at 4 °C with
primary antibody (24-1 1:200 and anti-CSN5 1:500). Controls reversing secon-
dary antibodies were performed to rule out cross-reaction. Fluorescence images
of cells were examined with a Leica DMR epifluorescence microscope.
2.8. SiRNA methods
The si-CSN5 sequence used was 5′-GCUCAGAGUAUCGAUGAAAdTdT-
3′ (CSN5 nucleotide 395 to 413; GenBank accession number NM_006837.2)
[38,39]. 7, 5.105 HeLa or HEK cells were transfected with Lipofectamine® and
Plus reagent (Invitrogen) with 200 pmol of siRNA. Cells were analyzed 48 h
after transfection. For functional assays, the control used was siCONTROL Non-
Targeting siRNA (all from Dharmacon Inc.): 5′-UAG-CGA-CUA-AAC-ACA-
UC-AA-UU-3′.Fig. 1. Interaction between CSN5 and wild-type (wt) or F508del-CFTR in heterologo
10% SDS-PAGE and subjected to immunoblots. The upper part of the co-immunopr
and the bottom with anti-CSN5 antibody (Ab). As a control, 30 μg of whole-cell ly
normalization) and anti-CSN5. Filled and empty arrowheads indicate the fully-and c
MAB25031 (anti-CFTR) from one 100 mm dish lysates of HEK 293 cells, transiently
(n=3). We used as negative control cells transfected with CSN5-V5 and the empty CF
vector (pcDNA3.1/V5-His Topo). CFTR was detected with West Dura reagent for an
anti-CSN5 Ab from two 100 mm dishes lysates of HEK 293 cells transiently co-transf
as a positive control lysates of HEK cells co-transfected with F508del-CFTR and CS
dishes lysates of HEK 293 cells transfected with pTracer, wt- or F508del-CFTR, and
Dura reagent and input membrane with ECL+. (D) HT-29 homogenates from two 75
mouse IgG (n=3). The blots were probed as in (C).2.9. Patch-clamp technique
Whole-cell patch-clamp recordings were performed at room temperature
(20–25 °C) on isolated cells as described elsewhere [32]. Currents were mo-
nitored by 300ms linear voltage ramps from−100 to +100mVwith an interpulse
interval of 10 s at 0 mV. Whole-cell capacitance and series resistance were
monitored throughout the recording and cells showing gradual changes in
these parameters were discarded. In experiments designed to record currents
from wt-CFTR expressing cells, the Cl− concentration of bath and pipette
solutions was reduced to 32 mM by equimolar replacement of chloride with
glutamate. Wt-CFTR and F508del-CFTR Cl− currents were activated by the
respective addition of 100 μMor 400 μM8-(4-chlorophenylthio)-cAMP sodium
salt (CPT-cAMP) to the external solution.
3. Results
3.1. CFTR interacts with CSN5 in vitro and in vivo
A yeast two-hybrid screening was performed to identify
proteins that interact with the third cytoplasmic loop of CFTR,
from amino acid Leu937 to Pro988 (according to the numbering
in sequence accession number NP_000483). Using this bait, aus and endogenous systems. Coimmunoprecipitated proteins were separated by
ecipitation (Co-IP) membrane was probed with MM13-4 antibody (anti-CFTR)
sates were loaded on a 10% SDS-PAGE, and probed with anti α-Tubulin (for
ore-glycosylated CFTR, respectively. (A) CFTR immunoprecipitation (IP) with
co-transfected with a CSN5-V5 fusion protein and F508del-CFTR or wt-CFTR
TR vector (pTracer) and cells co-transfected with wt-CFTR and the empty CSN5
enhanced signal sensitivity, CSN5 and α-Tubulin with ECL+. (B) CSN5 IP with
ected with a CSN5-V5 fusion protein and wt- or F508del-CFTR (n=3). We used
N5-V5, immunoprecipitated with MAB25031. (C) CFTR IP from two 100 mm
expressing endogenous CSN5 (n=3). Co-IP membrane was probed with West
cm2 flasks were subjected to anti-CSN5 IP (n=2), anti-CFTR IP (n=3) or anti-
Fig. 2. Localization of CSN5 in HeLa cells stably expressing wt- (spTC-wt), F508del-CFTR (spTCF-ΔF) or pTracer (spTracer) detected by immunofluorescence.
(A) Immunofluorescence analysis of CFTR and endogenous CSN5. CFTR is labeled with primary MAB25031 and Alexa Fluor 488-conjugated goat anti-mouse
IgG2a secondary Ab (green) and CSN5 is labeled with CSN5 Ab and Alexa Fluor 568-conjugated goat anti-mouse IgG2b secondary Ab (red). The nuclei are colored
in blue with Dapi. (B) Immunofluorescence analysis of CFTR and overexpressed CSN5-V5. The labeling is the same as in (A). For 13% of F508del-CFTR transfected
cells, we observed aggresome-like bodies in a perinuclear area (white arrows), also detected with white light microscopy.
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described in Materials and methods. Sequence analysis of
plasmids rescued from positive clones revealed that 9 clones
out of 36 were identical, and that these clones encoded a cDNA
insert with more than 9/10th of the human CSN5 coding se-
quence (amino acids 44–334). To verify interaction specificity
between CFTR and CSN5, we performed directed two-hybrid
experiments by mating the yeast strain AH109 Mat a containing
either pGBKT7-CL3wt, empty pGBKT7 and the pGBKT7-lam
containing lamin C, with the yeast strain Y187 Mat α con-
taining three of the nine CSN5 clones.
Interaction between the two full-length proteins was revea-
led by co-transfection of a CSN5-V5 tagged construct with
either wild-type or F508del-CFTR. The processing of CFTR
can be assessed by examining its glycosylation state [40]. In
our experimental conditions, electrophoresis of immunopre-
cipitated wild-type CFTR gave two bands (Fig. 1A). One was
a diffuse band of an approximate molecular mass of 170 kDa
(band C) that represented mature, fully glycosylated protein
that has processed through the Golgi complex. The second
was a thin band of about 140 kDa (band B) that represen-
ted the core-glycosylated protein located in the endoplasmic
reticulum. In F508del-CFTR expressing cells, only the in-
tracellular precursor is detectable due to impaired processing.Co-immunoprecipitation experiments (n=3) performed on ly-
sates of co-transfected HEK cells confirmed an association
between CSN5-V5 and wild-type or F508del-CFTR in vivo
(Fig. 1A). Reversing the antibodies (n=3) used for immuno-
precipitation and immunoblotting was difficult since CSN5 is
already known to interact with numerous protein partners,
therefore the amount of coimmunoprecipitated CFTR protein
is low (Fig. 1B). Anti-CSN5 immunoprecipitation of HEK
cell lysates expressing either wild-type or F508del-CFTR re-
vealed a unique CFTR band, the core-glycosylated form but
not the mature form. This clearly demonstrated that interac-
tion between CSN5-V5 and CFTR occurred with the immature
form of CFTR located in the endoplasmic reticulum. We further
confirmed this observation by repeating these co-immunopre-
cipitation experiments on HeLa cells stably expressing either
wild-type or F508del-CFTR and transfected with CSN5-V5.
These experiments showed an increased amount of CSN5-V5 in
the F508del-CFTR lysates precipitated with anti-CFTR anti-
body but an equal ratio CSN5/band B when compared to the
core-glycosylated form of CFTR, the interacting form of CFTR
with CSN5-V5 (data not shown). The distribution of CFTR and
CSN5 is different since part of CSN5 is present in the nucleus.
It explains the low abundance of CSN5 in Co-IP experiments
with endogenous CSN5 which is not proportional to the overall
Fig. 3. Effect of modulation of CSN5 expression on CFTR processing and function. (A) CFTR IP with MAB25031 from HeLa cells stably expressing wt- or F508del-
CFTR followed by in vitro PKA-phosphorylation. The cells were transiently transfected with an empty CSN5 vector (pcDNA3.1/V5-His Topo), siRNA CSN5 or
CSN5 and immonoprecipitated CFTR is separated by 5% SDS-PAGE. Filled and empty arrowheads indicate the fully- and core-glycosylated CFTR, respectively.
15 μg of whole-cell lysates were separated by 10% SDS-PAGE and probed with CSN5 Ab (bottom). (B) Quantification of CFTR B and C forms with ImageQuant 5.2
software. CFTR quantity is reported to the total protein quantity in the lysates. The mean±S.D. were obtained from three independent experiments.⁎pb0.05 is
determined by t-test. (C) Quantification of CFTR B form for F508del-CFTR expressing cells as in (B). The mean±S.D. were obtained from three independent
experiments. ⁎pb0.05 is determined by t-test. (D) Whole-cell patch-clamp experiments in HeLa cells±siRNA CSN5. The histogram shows the mean of more than six
independent experiments.
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expressed CSN5 is mostly cytoplasmic (data not shown). Sub-
sequently, we investigated the in vivo interaction of endogenous
CSN5with heterologous wild-type or F508del-CFTRwith twice
to thrice more cells. Endogenous CSN5-CFTR complexes were
precipitated from CFTR transiently transfected HEK cells but
not from mock-transfected cells (n=3): specific co-precipitation
of CFTR and CSN5 was detected by Western blot analysis
when anti-CFTR antibody was used for immunoprecipitation
(Fig. 1C).
Together, the results of these protein–protein interaction
assays and the yeast two-hybrid screen indicate that CFTR
specifically binds to CSN5, suggesting that we have identified
a novel interaction between CFTR and CSN5. This interaction
occurs with the core-glycosylated form of CFTR.
3.2. Endogenous CFTR interacts with endogenous CSN5
Since we have examined this interaction in two different
conditions, overexpressed CFTR together with over-or endo-
genously expressed CSN5, we then tested an endogenously
expressing CFTR cell line. HT-29 is a human colon adenocar-
cinoma cell line which expresses endogenously high levels of
CFTR [41]. As shown in Fig. 1D, endogenous CFTR interactedwith endogenous CSN5 using CFTR (n=3) or CSN5 (n=2)
antibodies for immunoprecipitation, neither CFTR nor CSN5
were detected when a non-relevant mouse IgG was used. As in
the heterologous expression system, this interaction only occurs
between CSN5 and the core-glycosylated form of CFTR.
3.3. Subcellular localization of endogenous and ectopic CSN5
Subcellular CSN5 localization was assessed in order to
evaluate its distribution, as CSN5 is a nuclear/cytoplasmic
shuttle protein known to interact with proteins in both com-
partments. Immunostaining was performed on stably transfec-
ted HeLa cells expressing either wild-type, F508del-CFTR or
pTracer. Wild-type and F508del-CFTR expressing cells exhib-
ited a cytoplasmic and nuclear staining but predominantly
cytoplasmic; wild-type cells exhibited a uniform cytoplasmic
whereas F508del-CFTR cells showed amore intense perinuclear
pattern (Fig. 2A). CSN5 over-expression increased the cyto-
plasmic but not the nuclear staining of CSN5 (data not shown)
and induced aggresome-like bodies (n=33) formation in
approximately 13% of F508del- (n=250 from three independent
transfections) but not in wild-type CFTR expressing cells
(n=250) (Fig. 2B). Taken together, these results indicate that a
fraction of CFTR and CSN5 present in a cell are co-distributed
Fig. 4. Pulse–chase experiments showing the turnover of mature and immature forms of wt- and F508del-CFTR in presence or absence of CSN5. (A) HEK 293 cells
are co-transfected with scramble siRNA (control) or siRNA CSN5, subjected to [35S]-pulse and MAB25031 IP after the indicated times. CFTR is separated by 5%
SDS-PAGE. Filled and empty arrowheads indicate the fully- and core-glycosylated CFTR, respectively. (B) PhosphoImager analysis of remaining [35S]-labeled B
forms of CFTR is represented as a function of time. Each line represents four independent experiments. ⁎pb0.05 is determined by paired t-test for F508del-CFTR+
siRNA CSN5 compared to the other conditions.
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maturation.
3.4. Effect of CSN5 on CFTR maturation and function
To examine the possible role of CSN5 in the biogenesis of
CFTR protein, stably transfectedHeLa cells expressing either wild-
type or F508del-CFTR were transfected with three different
constructions: one encoding the full-length and non tagged CSN5
protein, a CSN5-specific siRNA and an empty vector. Loss-of-
function studies reduced endogenous CSN5 expression by RNA-
mediated interference down to 10% of endogenous protein level
(Fig. 3A). Immunoprecipitation experiments at steady-state sho-
wed that wild-type and F508del cells did not react the same way
to CSN5 expression variations. Total wild-type CFTR abundance
(n=3) was increased by a twofold after CSN5 over-expression
(pb0.006) and a fourfold after CSN5 down-regulation (pb0.002)
(Fig. 3B). However, densitometry analysis revealed that the rela-
tive amount of band C or band B with respect to total CFTR was
identical in all conditions suggesting an unchanged processing
efficiency (ratio C/B+C= 88±2%). Regarding F508del-CFTR,
overexpressing CSN5 led to a 25% decrease in F508del-CFTR
protein (p=0.05) whereas down-regulation of CSN5 led to a 50%
increase (p=0.002) (n=3) (Fig. 3C). In both experimental con-
ditions, no mature CFTR was observed indicating that even if
the stability of the mutant CFTR could be modulated, the pro-
cessing of CFTR was not modified (Fig. 3A).
The elevated amount of fully-glycosylated-CFTR observed
after CSN5 down-regulation prompted us to test its repercussion
on chloride channel activity, using the whole-cell patch-clamp
technique. None of the mock-transfected cells displayed Cl-cur-
rents in either basal or cAMP-stimulated conditions [32]. Ad-
dition of 100 μM CPT-cAMP to the bath solution induced large
chloride currents in wild-type CFTR expressing cells transfec-
ted with siCONTROL. For example, peak current amplitudemeasured at −60 mV reached 76.7±19.6 pA/pF (n=7). These
currents were completely inhibited in the presence of 20 μM of
the specific CFTR inhibitor, CFTR(inh)-172 (data not shown). As
shown in Fig. 3D, no significant difference in current amplitude
could be observed when wt-CFTR cells were transfected with
siCSN5 (mean amplitude at −60 mV: 72.3±12.2 pA/pF, n=8).
These data indicate that the elevated amount of mature CFTR
observed in the biochemical experiments was not correlated with
increased chloride current. These results are compatible either
with an increase of intracellular vesicular pool of CFTR without
additional insertion into the plasma membrane, or by increased
internalization of mature CFTR.
The biochemical study of stable F508del-CFTR cells trans-
fected with siCSN5 showed an increase amount of band B but no
band C. Whole-cell voltage-clamp analysis of F508del-CFTR
HeLa cells transfected either with control (n=7) or with siCSN5
(n=17) was first performed using the same experimental con-
ditions as for wild-type CFTR. In these conditions, stimula-
tion of the cells with 100 μMCPT-cAMP was without effect. To
maximize our ability to detect differences between the two
transfection experiments, we used internal and external solutions
containing 135 mM Cl− and stimulated the cells with 400 μM
CPT-cAMP. Activated chloride currents were of small amplitude
and detectable only in a low number of cells tested. The mean
amplitude of the currents recorded at−60 mV from siCSN5 cells
(2.12±0.8 pA/pF, n= 7) and control cells (3.83±3.14 pA/pF,
n=6) were not significantly different (Fig. 3D). These results
thus indicate that extinction of CSN5 in F508del cells did
not correct misprocessing of the protein even if the amount of
core-glycosylated CFTR was enhanced.
3.5. Down-regulation of CSN5 stabilizes F508del-CFTR
To examine the possibility that CSN5 affected the turnover
of the CFTR protein, we performed pulse–chase experiments in
Fig. 5. Effect of a dominant negative form of CSN5 on F508del-CFTR processing. (A) CSN5 constructions in pcDNA3.1/V5-His Topo plasmid, CSN5-V5 simut and
CSN5-D151N-V5 simut contained 4 silent mutations at amino acids 23 and 24, in the region targeted by siRNA CSN5. (B) Immunoblots of HEK 293 cells lysates
transiently transfected by the different constructions of CSN5±siRNA CSN5. (C) Pulse–chase experiments in HEK 293 cells transiently co-transfected by F508del-
CFTR, CSN5-D151N-V5 simut and siRNA CSN5, treated as in Fig. 4. Our control is transfected by pcDNA3.1/V5-His Topo and scrambled siRNA. siRNA CSN5, is
co-transfected with the pcDNA3.1/V5-His Topo, and CSN5-D151N-V5 simut is co-transfected with siRNA CSN5. (D) PhosphoImager analysis of remaining B forms
of F508del-CFTR is represented as a function of time as shown in Fig. 4B. Each line represents three independent experiments.
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expression, as this latter showed an increased CFTR expression.
In wild-type and F508del-CFTR HEK transfected cells (n=4),
the turnover of the core-glycosylated form of CFTR was iden-
tical under control conditions whereas down-regulation of CSN5
had an opposite effect (Fig. 4). Down-expression of CSN5 led to
an increased turnover of the core-glycosylated form of wild-type
CFTR (Fig. 4B). Disappearance of band B could be due to both
degradation and maturation (conversion to band C); as the
amount of total wild-type CFTR protein is increased (Fig. 3B),
we can postulate either to an increase of maturation efficiency
or to a decrease in the degradation rate. Therefore, it is difficult
to conclude as the majority of the core-glycosylated precursor
is degraded, and a fraction is converted to the mature fully-
glycosylated CFTR. In the case of F508del-CFTR HEK trans-
fected cells, such an approach is more straightforward as
almost 100% of the core-glycosylated CFTR is degraded. CSN5
down-expression doubled band B stability, with a half-life of
120 instead of 60 min. Furthermore this twofold increase of the
half-life is associated to a slower disappearance kinetic of
band B with significantly different percentages of remaining
B form at 2 (pb0.0003) and 3 h (pb0.03) compared to control
conditions. We could not observe the appearance of band C
and concluded that the increased band B stability resulted from
a decrease in its degradation rate. CSN5 down-expression did
not interfere with the normal activity of ERQC factors already
known to act in the selection of CFTR degradation (Hsc70,calnexin, ubiquitinylation), thus silencing CSN5 did not mo-
dify CFTR degradation pathway in HEK cells (Supplementary
Figure).
3.6. CFTR stabilization is not due to the loss of CSN5
isopeptidase activity
Two biological activities have been described for the CSN5
subunit of the signalosome: an isopeptidase activity which is
carried out by CSN5 and a kinase activity which is associated
with CSN [42,43]. The covalent addition of a small ubiquitin-
related protein called NEDD8 to a lysine residue of cullins
(neddylation) facilitates the recruitment of ubiquitin-conjugated
E2 and the assembly to the SCF complexes [44]. Deneddyla-
tion, which removes the NEDD8 moiety, requires the isopepti-
dase activity of CSN5 [45]. To determine whether the loss of
isopeptidase activity was responsible of the stabilization of core-
glycosylated F508del-CFTR, we introduced four silent muta-
tions in the siRNA target sequence of wild-type CSN5-V5
(CSN5-V5 simut). We also constructed a dominant-negative
form of CSN5 also containing the four silent mutations, D151 N-
CSN5-V5 simut (Fig. 5A), this mutation abolishes isopeptidase
activity but does not affect CSN complex assembly [42]. We
first co-transfected each V5-tagged CSN5 with siRNA CSN5
and assessed the efficiency of endogenous CSN5 silencing to-
gether with over-expression of each construct (Fig. 5B). We
then performed pulse–chase experiments in these conditions
Fig. 6. Effect of an inhibitor of the CSN-associated kinases, piceatannol, on CFTR processing. (A) HeLa cells stably expressing wt- or F508del-CFTR were treated for
4 h with 20 μM piceatannol or DMSO as a control. CFTR IP with MAB25031 were treated as in Fig. 1C and D. Filled and empty arrowheads indicate the fully-and
core-glycosylated CFTR, respectively. (B) Quantification of the CSN5 immunoprecipitates reported to the quantity of B form of CFTR with GeneTools software. The
histogram represents three independent experiments. ⁎pb0.05 is determined by t-test for piceatannol treatment compared to DMSO. (C) HEK 293 cells transfected
with F508del-CFTR were treated 16 h with 20 μM piceatannol or DMSO (control), then subjected to pulse–chase experiments as in Figs. 4 and 5. (D) PhosphoImager
analysis of remaining B forms of F508del-CFTR as a function of time. Each line represents four independent experiments. ⁎pb0.05 is determined by paired t-test.
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turnover of the core-glycosylated form of CFTR was identi-
cal under control conditions and after over-expression of the
dominant-negative form of CSN5 (Fig. 5D). Therefore, the
decrease in the degradation rate of core-glycosylated F508del-
CFTR is not related to the loss of isopeptidase activity of CSN5
but may be caused by a lack of CSN-associated factors whose
activity may depend on the presence of intact CSN rather than
CSN isopeptidase activity itself.
3.7. Piceatannol, an inhibitor of the CSN-associated kinases,
stabilizes CSN5/CFTR interaction
Our experiments pointed towards a role of CSN5 in CFTR
degradation. Since CSN5 is part of the signalosome, this sug-
gested an involvement of this complex in this process. All
the models proposed for the mechanism of action of CSN in
protein degradation involve CSN-associated kinase activity.
We reasoned that if these kinases are involved in CFTR
degradation, their inhibition may influence CSN5-CFTR inter-
action. We have evaluated the effect of piceatannol, a newly
described potent inhibitor of CSN-associated kinases [46], on
CFTR degradation. This compound was chosen because it has
a low IC50 value and is less toxic compared to other CSN kinase
inhibitors. Fig. 6A shows the results of a co-immunoprecipita-tion experiment in which the effects of piceatannol on CSN5/
CFTR interaction were compared on stably transfected HeLa
cells expressing endogenously CSN5 (n=3). We found that
piceatannol increased the amount of CSN5 that coimmunopre-
cipitated with CFTR without changing the amount of endogen-
ous CSN5 in whole-cell lysates (Fig. 6A). When quantified,
the CSN5/B band ratio was 3±1 fold higher (pb0.05) in treated
compared to control cells (Fig. 6B). This suggests that pice-
atannol treatment enhanced the interaction between CSN5 and
the core-glycosylated form of CFTR. A possible explanation for
this increased interaction could be that when kinases are
inhibited, client protein may not be released, and degradation
delayed. Finally, we performed pulse–chase experiments (n=4)
and showed that piceatannol reduced CFTR degradation with
significantly different percentages of remaining B form at 2
(pb0.05) and 3 h (pb0.05) compared to control conditions
(Fig. 6C and D), suggesting that kinase activity associated with
the CSN complex is partly involved in the degradation of core-
glycosylated CFTR.
4. Discussion
CSN5 was first identified as a co-activator of c-Jun (Jab1)
[21] and then as the fifth component of the signalosome. In
addition to its interaction with c-Jun and subunits of the CSN,
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The COP9 signalosome is a highly conserved multiprotein
complex paralogous to the lid of the 26S proteasome. It is
implicated in a large array of processes that has been attributed to
its regulation of protein stability by interfering with the ubiquitin
proteasome pathway via deneddylation and phosphorylation.
Among CSN5-interacting proteins, those which stability is
affected upon modulation of CSN5 expression, are all known
to be polyubiquitinylated [48]. Indeed, CSN is involved in
regulation of the stability of proteins such as HIF-1α [38,49],
SMAD7 [39] and estrogen receptor α [50], which are substrates
of the ubiquitin proteasome system. How CSN5 can interact
with such a large number of proteins is currently undetermined
(reviewed in Ref. [45,48]). No common domains within these
proteins have been defined suggesting that either a common
post-translational modification and/or a common structural
feature is involved. CFTR as a polyubiquitinylated transmem-
brane protein is therefore a potential CSN5 target.
The present study shows that CSN5 binds to CFTR and that
this interaction occurs with the core-glycosylated form of the
protein. Over-expression of CSN5 led to a 25% decrease of
F508del-CFTR whereas down-expression prevented degrada-
tion by decreasing the degradation rate but did not enhance cell
surface expression. Thus disrupting the signalosome delays but
does not prevent the delivery of the misfolded and mutated
immature CFTR to the ubiquitin proteasome pathway. CSN
associates with protein kinases [43] and serves as a docking site
for the phosphorylation of various substrates. Treatment of
cells with piceatannol, the most potent CSN kinase inhibitor,
stabilized CSN5/CFTR interaction and reduced F508del-CFTR
degradation but not as efficiently as CSN5 silencing. The sta-
bilizing effect observed is consistent with an inhibition of the
degradative pathway. This implies that degradation of F508del-
CFTR is partly triggered by the interaction of CSN5 with the
misfolded core-glycosylated protein.
Down-expression of CSN5 increased significantly wild-type
CFTR protein amounts by a fourfold. As almost 80% of wild-
type CFTR is misfolded and retained in the ER, this increased
amount of CFTR could result of misfolded wild-type CFTR
being processed through post-ER compartments. Modulation of
CSN5 expression did not modify the processing efficiency as
the ratio of core- and fully-glycosylated forms of CFTR was
unchanged in wild-type cells. Disappearance of wild-type CFTR
band B results from both degradation and maturation. Therefore,
the decreased degradation rate associated with CSN5 knock-
down, as observed in F508del-CFTR expressing cells, should
be partly masked by increased maturation in wild-type cells.
The apparent increased turnover of wild-type CFTR band B
could result from the combination of enhanced misfolded CFTR
processing with delayed degradation of core-glycosylated form
of wild-type CFTR.
CSN5 is present in cells both within the CSN complex and
in smaller CSN complexes or in CSN-independent forms and
CSN5 activity varies depending on its location and associa-
tion. Therefore, it is difficult to predict the outcome of CSN5
over-expression or down-expression in this context. CSN5 over-
expression increases CSN5 but does not increase the COP9signalosome whereas CSN5 down-regulation gives rise to an
altered signalosome lacking CSN5 subunit and thus isopepti-
dase activity and docking site for client proteins. This is an
unbalanced effect of CSN5 expression. Although CSN5 plays
an essential role in phosphorylation, deneddylation, and pro-
tein stability, it remains to be determined how these activities
are regulated and the form interacting with CFTR still remains
to be characterized. CSN5 is found both in the cytosol and in
the nucleus whereas the CSN complex is predominantly pe-
rinuclear/nuclear. When ectopic expression of CSN5 is per-
formed, most of the excess protein is found in the cytosol in a
CSN-independent form [51]. We have performed experiments
in various conditions: ectopic over-expression, endogenous ex-
pression and extinction of CSN5. The subcellular distribution
of CSN5 in cells expressing wild-type or F508del-CFTR is
different, endogenous CSN5 being predominantly cytoplasmic
in both cells but exhibiting a uniform staining in wild-type cells
and a perinuclear staining in F508del-CFTR cells. We cannot
infer whether CSN5 acts as a monomer or as part of the CSN
complex; the more intense perinuclear staining observed in
F508del-CFTR expressing cells is consistent with a predomi-
nant role of CSN5 within the CSN complex, bringing misfol-
ded FTR to the degradative pathway. Experimental evidences
point towards a role of CSN5 as part of this pathway since CSN5
over-expression induces aggresome-like bodies formation in
F508del-but not in wild-type CFTR cells. These effects are
analogous to those of proteasomal inhibitors which lead to the
accumulation of aggregated polyubiquitinylated F508del-CFTR
in the cytoplasm but cannot rescue its surface expression [52].
Overall, our data showed: i) a striking stabilization asso-
ciated to a slower disappearance kinetic of core-glycosylated
F508del-CFTR after CSN5 silencing, and ii) an intermediate
stabilization of F508del-CFTR when CSN-associated kinases
were inhibited. Reduction of any subunit of the CSN results in
the destabilization of the entire CSN [53] and kinase activity
is not specific to CSN5 but to CSN2 in the context of the
holocomplex. Therefore, our data give evidences for a CSN-
associated role of CSN5 in regulating misfolded core-glycosy-
lated form of CFTR, targeting immature CFTR to the degra-
dation pathway. Hence, CSN5 knockdown disrupts CSN5/
misfolded CFTR interaction prolonging the time for correct
folding. In the case of wild-type CFTR, this led to a dramatic
increase in total CFTR protein and in the case of F508del-CFTR
to a slower degradation rate without changing the fate of the
mutated protein.
CSN and the lid subcomplex of the proteasome share
structural similarities suggesting a functional relationship bet-
ween CSN and the ubiquitin proteasome system. It has been
proposed that CSN may act as an alternative lid for the pro-
teasome named the COP9 proteasome [53,54] or as an assembly
platform for cullin ubiquitin ligases [55]. Our data point to-
wards an association between misfolded CFTR and the CSN
via its fifth component targeting this misfolded protein to
degradation. When misfolded CFTR is associated to CSN5, the
equilibrium between 26S proteasome and CSN might shift to
produce the COP9 proteasome. This latter pathway gives new
insights into an alternative CFTR degradation pathway that
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teasome inhibitors in preventing CFTR degradation [7].
Newly synthesized F508del-CFTR is degraded in a pre-Golgi
compartment and sent to premature degradation through an
Hsc70-CHIP-UbcH5 complex [56]. Regarding to a recently pro-
posed model, wild-type and F508del-CFTR undergo ERAD
from two distinct checkpoints [57]. Since then several interac-
tions and new factors, that select misfolded CFTR for degrada-
tion have been identified [58–60]. The temporal recruitment of
these factors remains to be determined but we can speculate that
CSN5/CFTR interaction occurs early at this decision point.
In this context, identifying CSN5 as a new component of the
degradative pathway is an important step towards the goal of
deciphering the sorting between misfolded and correctly folded
CFTR protein.
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